Fundraising Fox

Korsana

Waltham, US · 32 employees on LinkedIn · 7 known investors

Find your way into Korsana

45 people in our graph share verified history with the Korsana team — schools, employers, funds. One of them is your warm intro.

Brandon Sheltonunlockedknows Jonathan Violin · together at Duke University - The Fuqua School of Business (overlapped)
×7knows the team · via Duke University - The Fuqua School of Business
knows the team · via Korsana
×3knows the team · via UC San Diego School of Medicine

Korsana develops technology to deliver large-molecule biologic drugs across the blood-brain barrier using transferrin receptor shuttling, aimed at treating neurodegenerative diseases such as Alzheimer's. Its approach uses antibody engineering to enable therapies with meaningful central nervous system exposure delivered subcutaneously.

BiotechDeep TechHealthtech

Founders & leadership

MVMark Vignola
Mark VignolainChief Financial Officer
JVJonathan Violin
Jonathan ViolininPresidentExecutive Officer, Director at Dianthus Therapeutics

Investors · 7

Sanofi VenturesCambridge · $5M
TCG CrossoverPalo Alto
VenrockreportedPalo Alto · $500K – $10M
Wellington ManagementreportedBoston · $5M – $50M

Also in the syndicate · 3

FairmountJ.P. Morgan Life Sciences Private CapitalTCGX

Funding

SEC filings, press & company announcements

$175M disclosed across 1 of 2 rounds · 2026

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

3 people who came through Korsana went on to found or lead other companies.

Jonathan ViolinPresidentFounded Viridian Therapeutics +1Nimish ShahCo-Founder and Board DirectorFounded Apogee TherapeuticsAndrew GottesdienerCo-Founder and Board MemberFounded Apogee Therapeutics

In the news

Korsana raises $175M for Alzheimer's therapybioxconomy.com · Feb 2026Korsana Biosciences Emerges From Stealth With $175 Millon In Funding — TradingView Newstradingview.com · Feb 2026An Alzheimer’s startup emerges with $175M in venture backing | BioPharma Divebiopharmadive.com · Feb 2026Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseasesbusinesswire.com · Feb 2026Korsana Biosciences Raises $175M in Fundingfinsmes.com · Feb 2026Korsana Biosciences raises $175 million to advance Alzheimer’s antibody therapystatnews.com · Feb 2026

Frequently asked questions

What does Korsana do?
Korsana develops technology to deliver large-molecule biologic drugs across the blood-brain barrier using transferrin receptor shuttling, aimed at treating neurodegenerative diseases such as Alzheimer's. Its approach uses antibody engineering to enable therapies with meaningful central nervous system exposure delivered subcutaneously.
Who are Korsana's investors?
Korsana's investors include Sanofi Ventures, TCG Crossover, Venrock, Wellington Management.
How much funding has Korsana raised?
Korsana has disclosed $175M raised across 1 of its 2 known rounds.
Where is Korsana headquartered?
Korsana is headquartered in Waltham, US.